Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Type 1 diabetes mellitus.

Anastasia Katsarou1, Soffia Gudbjörnsdottir2,3, Araz Rawshani2,3

  • 1Department of Clinical Sciences, Lund University, Skåne University Hospital, Jan Waldenströms gata 35, 20502 Malmö, Sweden.

Nature Reviews. Disease Primers
|March 31, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retinol, Carotenoid, and Tocopherol Intake and Status, and the Risk of Islet Autoimmunity and Type 1 Diabetes: The Environmental Determinants of Diabetes in the Young Study.

Diabetes/metabolism research and reviews·2026
Same author

Prediction of cardiac arrest in patients with heart failure in Sweden: a registry study with development of a machine learning model.

BMJ open·2026
Same author

Standardised, telemonitored titration of guideline-directed medical therapy in heart failure is associated with faster optimisation and improved persistence compared to standard of care.

Open heart·2026
Same author

When Randomization Is Not Enough: Divergent Beta-Blocker Trials and the Illusion of Universal Causality.

European heart journal. Cardiovascular pharmacotherapy·2026
Same author

Characteristics and outcomes after out-of-hospital cardiac arrests in individuals with pre-existing psychiatric conditions, compared to those without.

Resuscitation plus·2026
Same author

Sex differences in cardiomyopathies: Presentation, diagnostic evaluation, and outcomes in a prospective cohort.

International journal of cardiology·2026
Same journal

Accidental hypothermia.

Nature reviews. Disease primers·2026
Same journal

Accidental hypothermia.

Nature reviews. Disease primers·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Buruli ulcer in Africa: between innovation and pragmatism.

Nature reviews. Disease primers·2026
Same journal

Author Correction: Atopic dermatitis.

Nature reviews. Disease primers·2026
See all related articles
This summary is machine-generated.

Type 1 diabetes mellitus (T1DM) is an autoimmune disease causing insulin deficiency and hyperglycemia. Early biomarkers like autoantibodies can identify at-risk individuals, but a cure remains elusive, necessitating improved treatments and early diagnosis.

Area of Science:

  • Immunology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Type 1 diabetes mellitus (T1DM) is a chronic autoimmune condition resulting in insulin deficiency and hyperglycemia due to pancreatic beta-cell destruction.
  • While often diagnosed in youth, T1DM can manifest later in life, with pathogenesis linked to T-cell mediated beta-cell attack.
  • Islet-targeting autoantibodies serve as crucial biomarkers for T1DM-associated autoimmunity, detectable years before symptom onset.

Purpose of the Study:

  • To summarize the current understanding of Type 1 diabetes mellitus (T1DM) pathogenesis, diagnosis, and treatment.
  • To highlight the role of autoantibodies as early biomarkers for T1DM risk.
  • To emphasize the need for advancements in T1DM management and prevention strategies.

Main Methods:

Related Experiment Videos

  • Review of existing literature on T1DM etiology, pathogenesis, and clinical manifestations.
  • Analysis of the role of islet-targeting autoantibodies in T1DM autoimmunity.
  • Discussion of current and emerging therapeutic approaches for T1DM management.

Main Results:

  • T1DM pathogenesis involves T-cell mediated beta-cell destruction, with autoantibodies predicting disease onset.
  • Disease progression can be staged based on hyperglycemia and associated symptoms.
  • Despite advances in insulin therapy and glycemic control, microvascular and macrovascular complications persist.

Conclusions:

  • Early diagnosis and prevention of beta-cell loss are critical for improving T1DM patient outcomes.
  • Development of novel therapeutic strategies is essential to enhance quality of life and prognosis.
  • Lifelong insulin therapy remains the standard, with ongoing innovation in delivery and monitoring systems.